Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Extension study of SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock cardiogenic shock due to heart failure(SEISMiC B)

Next Previous
Search
Trial Profile

Extension study of SEISMiC Phase 2 Study of Istaroxime in Early Cardiogenic Shock cardiogenic shock due to heart failure(SEISMiC B)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 23 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Istaroxime (Primary)
  • Indications Cardiogenic shock; Decompensated heart failure
  • Focus Therapeutic Use
  • Acronyms SEISMiC B; SEISMiC Part-B
  • Sponsors Windtree Therapeutics

    • Most Recent Events

    • 16 Dec 2024 Status changed from active, no longer recruiting to completed According to a Windtree Therapeutics media release.
    • 16 Dec 2024 According to a Windtree Therapeutics media release, company recently showcased promising data on istaroxime, an investigational treatment for early cardiogenic shock, at the Cardiovascular Clinical Trials Conference in Washington, DC. The presentation, delivered by renowned cardiogenic shock expert Dr. Alexandre Mebazaa, highlighted the findings from the Phase 2b SEISMiC B study.
    • 21 Oct 2024 According to a Windtree Therapeutics media release, positive topline data from this study will be presented at the ThinkEquity Conference on Oct 30th at 12:30pm ET

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top